Indication: Bladder Cancer
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma
Sub-indication: Genitourinary Cancer
Study Type: Drug Study
Principal Investigator: Chandler Park, M.D.Norton Cancer Institute
Sponsor: Sponsor: Mirati Therapeutics, Inc
Learn more at ClinicalTrials.gov
Email for more information: GU-NCIResearch@nortonhealthcare.org
